Amneal Adds Four New Products to Its Growing Portfolio

Amneal Pharmaceuticals has launched four new products since June 2015. On 13 July, the company obtained FDA approval for its tobramycin inhalation solution (a generic equivalent for Tobi inhalation solution); it is the first inhalation solution formulation offered by Amneal. On 11 July, Amneal started shipping memantine HCl immediate release tablets in 5 mg and 10 mg strengths. This product is one of the first generic equivalents to Namenda on the market.

“We developed memantine at a customer’s request. For some time, patients and payers have been eagerly awaiting availability of this generic product, and now we are pleased to be one of the first manufacturers to bring it to market,” explains Amneal Co-CEO & Chairman Chirag Patel. “It’s one of those products that brings value to everyone in the healthcare supply chain: our customers, the patients, and the payers. Tobramycin is extremely exciting for us in that it’s a new dosage form for Amneal — proof we’re delivering the varied portfolio we committed to offering our customers.”